Want to see XFOR full AI Analyst Report?
Top Page
X4 Pharmaceuticals
(NASDAQ:XFOR)
Select Model
Select Model
Rating:52Neutral
Price Target:
$4.50
▲(4.90% Upside)
Action:Reiterated
Date:07/02/26
The score is held back primarily by weak financial performance—large ongoing losses, volatile revenue, and heavy cash burn—despite improved leverage. Technicals are comparatively supportive with the stock trading above major moving averages, while valuation is constrained by negative earnings and no dividend. Corporate events are mildly positive overall but include dilution risk.
Positive Factors
Improved leverage and balance-sheet flexibility
A dramatic reduction in debt to roughly $0.7M from ~$77–78M materially lowers interest and refinancing risk and increases strategic optionality. With sizable equity (~$168M) and assets (~$270M), the company now has more balance-sheet flexibility to fund trials, commercial rollout or M&A without immediate debt pressure.
Negative Factors
Persistent and large cash burn
Consistent negative operating cash flow (~-$93M TTM) and negative free cash flow (~-$73M TTM) mean the company consumes capital to fund operations and trials. This structural cash burn requires recurrent external financing or large revenue upside; both raise dilution or execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage and balance-sheet flexibility
A dramatic reduction in debt to roughly $0.7M from ~$77–78M materially lowers interest and refinancing risk and increases strategic optionality. With sizable equity (~$168M) and assets (~$270M), the company now has more balance-sheet flexibility to fund trials, commercial rollout or M&A without immediate debt pressure.
Read all positive factors
X4 Pharmaceuticals (XFOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$373.51M
Dividend YieldN/A
Average Volume (3M)842.03K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth-71.26%
EPS Growth-300.04%
CountryUS
Employees45
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.54
Shares Outstanding94,319,695
10 Day Avg. Volume1,582,561
30 Day Avg. Volume842,034
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)4.82
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue26.88
Enterprise Value/Gross Profit33.84
Enterprise Value/Ebitda-2.70
Forecast
1Y Price Target
$11.67Price Target Upside171.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$9.07M
X4 Pharmaceuticals Business Overview & Revenue Model
Company Description
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is ...
How the Company Makes Money
null...
X4 Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 01, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and global expansion efforts, supported by a strong financial position and promising market research. However, challenges remain in sales consistency and the brief commercial history in the WHIM market.Positive Updates
Clinical Trial Advancements
X4 advanced the 4WARD Phase III trial for chronic neutropenia (CN), with over 90% of global trial sites activated and a finalized trial design based on regulatory feedback.
Negative Updates
Sales Fluctuations
Quarterly sales of XOLREMDI were slightly lower than the previous quarter due to inventory resupply timing and market lumpiness.
Read all updates
Q1-2025 Updates
Positive
Negative
Clinical Trial Advancements
X4 advanced the 4WARD Phase III trial for chronic neutropenia (CN), with over 90% of global trial sites activated and a finalized trial design based on regulatory feedback.
Read all positive updates
Company Guidance
During the X4 Pharmaceuticals Q1 2025 financial call, the company provided several key metrics and updates. The 4WARD trial, a pivotal Phase III study for mavorixafor in chronic neutropenia (CN), is actively enrolling participants with over 90% of global trial sites activated. The trial aims to demonstrate statistically significant improvements in absolute neutrophil count (ANC) response and reductions in annualized infection rates, targeting a CN population of about 15,000 in the US with high unmet medical needs. The trial is powered at over 95% for the ANC endpoint and over 90% for infection rate outcomes. X4 anticipates full enrollment by Q3 or Q4 2025, with top-line data expected in H2 2026. Financially, X4 reported ending Q1 with just under $90 million in cash, with cumulative XOLREMDI sales reaching $3.5 million since its May 2024 launch. Additionally, the company highlighted its strategic partnerships for expanding mavorixafor's reach globally, including expected EMA approval by Q1 2026.X4 Pharmaceuticals Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.01M | 35.11M | 2.56M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.16M | 28.86M | 1.76M | 0.00 | 0.00 | -1.89M |
| EBITDA | -89.86M | -69.00M | -27.58M | -94.89M | -89.33M | -83.14M |
| Net Income | -99.72M | -79.20M | -37.45M | -101.17M | -93.87M | -88.70M |
Balance Sheet | ||||||
| Total Assets | 270.28M | 290.46M | 146.45M | 147.26M | 155.59M | 117.18M |
| Cash, Cash Equivalents and Short-Term Investments | 233.72M | 253.00M | 102.06M | 114.22M | 121.72M | 81.79M |
| Total Debt | 77.25M | 77.28M | 78.09M | 58.28M | 38.42M | 39.78M |
| Total Liabilities | 101.83M | 104.17M | 124.30M | 96.16M | 81.53M | 52.76M |
| Stockholders Equity | 168.45M | 186.29M | 22.15M | 51.10M | 74.05M | 64.41M |
Cash Flow | ||||||
| Free Cash Flow | -73.25M | -88.62M | -138.23M | -96.57M | -77.20M | -71.52M |
| Operating Cash Flow | -92.85M | -85.62M | -130.90M | -96.51M | -77.10M | -70.91M |
| Investing Cash Flow | 30.54M | 8.15M | 66.99M | -14.88M | -103.00K | -615.00K |
| Financing Cash Flow | 238.63M | 238.63M | 20.29M | 88.52M | 117.23M | 74.25M |
X4 Pharmaceuticals Technical Analysis
Negative
4.29
Price Trends
4.07
Negative
3.98
Negative
3.82
Positive
Market Momentum
>-0.01
Positive
47.09
Neutral
12.48
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XFOR, the sentiment is Negative. The current price of 4.29 is above the 20-day moving average (MA) of 4.06, above the 50-day MA of 4.07, and above the 200-day MA of 3.82, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.09 is Neutral, neither overbought nor oversold. The STOCH value of 12.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XFOR.
X4 Pharmaceuticals Risk Analysis
X4 Pharmaceuticals disclosed 65 risk factors in its most recent earnings report. X4 Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
X4 Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $164.42M | -3.20 | 107.73% | ― | ― | 36.33% | |
53 Neutral | $199.16M | -7.87 | -61.43% | ― | -100.00% | 18.25% | |
52 Neutral | $373.51M | -0.87 | -94.90% | ― | -71.26% | -300.04% | |
52 Neutral | $138.92M | -1.07 | -225.59% | ― | -9.79% | 82.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $66.66M | -0.83 | -68.98% | ― | ― | -26.14% |
* Healthcare Sector Average
XFOR
X4 Pharmaceuticals
3.96
2.53
176.92%
CBUS
Cibus
1.90
0.34
21.79%
NRXP
NRX Pharmaceuticals
4.11
0.90
28.04%
EQ
Equillium
2.96
2.61
748.14%
PMVP
PMV Pharmaceuticals
1.24
-0.02
-1.59%
X4 Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
X4 Pharmaceuticals Expands Board with New Independent Director
Positive
Jul 1, 2026
On June 30, 2026, X4 Pharmaceuticals appointed CAMP4 Therapeutics Chief Financial Officer Kelly Gold as a Class II, independent director effective July 1, 2026, expanding its board from five to six members and adding her to the audit committee. Th...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
X4 Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan
Positive
May 12, 2026
At its recent Annual Meeting, X4 Pharmaceuticals’ stockholders approved an increase of 1,500,000 shares available under the company’s Second Amended and Restated 2017 Equity Incentive Plan, reinforcing the firm’s ability to use s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.